(2014). Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. Bmj. http://doi.org/10.1136/bmj.g2780.
(2015). Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab. http://doi.org/10.1111/dom.12431.
(2016). Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med. http://doi.org/10.1001/jamainternmed.2016.1531.
(2018). Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k4880.
(2021). Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients with Type 2 Diabetes. Clin Pharmacol Ther. http://doi.org/10.1002/cpt.2430.